Pure Global
NCT06347198

Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer

A Single-center Exploratory Clinical Study of Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer
Wuhan Union Hospital, China·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Metastatic Colorectal Cancer
Drug/Device/Intervention
Fruquintinib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Wuhan Union Hospital, China
Location
Wuhan, China
Timeline & enrollment
Phase
Phase 1
Start date
Apr 10, 2024
End date
May 01, 2025
Enrollment
30 participants
Primary outcome

Intestinal microbiota diversity, abundance and taxonomic information,adverse events

Summary

This is a single-center exploratory clinical study to explore the efficacy and safety of Oral
 Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment
 in Metastatic Colorectal Cancer.

ICD-10 classifications
Malignant neoplasm of colonMalignant neoplasm: Colon, unspecifiedMalignant neoplasm: Descending colonMalignant neoplasm: Ascending colonMalignant neoplasm: Overlapping lesion of colon
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06347198
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06347198 through Pure Global AI's free database. This Phase 1 trial is sponsored by Wuhan Union Hospital, China and is currently Recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.